A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
Public ClinicalTrials.gov record NCT02873351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of L-DOPA Safety and Tolerability in Patients With AMD, and Proof of Concept That L-DOPA Improves Surrogate Biomarkers in Patients With Moderate to Advanced AMD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with AMD, and measure the effects on surrogate functional biomarkers of AMD.
Study identification
- NCT ID
- NCT02873351
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2019
- Primary completion
- Nov 30, 2020
- Completion
- Nov 30, 2020
- Last update posted
- Apr 4, 2019
2019 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Robert W Snyder, MD, PhD, PC | Tucson | Arizona | 85712 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Age-related Macular Degeneration trials
Other public records listing Age-related Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT06662162: Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration Recruiting
- NCT06237127: Effects of Goji vs. Fiber on Macular Degeneration Recruiting
- NCT05300724: An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration Active, not recruiting
- NCT07605468: Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension Not yet recruiting
- NCT07594236: Phase 1 Study of C.001 in Retinal Degeneration Recruiting
- NCT06593405: The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02873351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2019 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02873351 live on ClinicalTrials.gov.